THE VIEWS EXPRESSED IN THIS ARTICLE ARE THOSE OF THE AUTHOR AND DO NOT REFLECT THE OFFICIAL POLICY OR POSITION OF THE UNITED STATES AIR FORCE, DEPARTMENT OF DEFENSE, OR THE U.S. GOVERNMENT. METABOLISM OF ENDOSULFAN-ALPHA BY HUMAN LIVER MICROSOMES AND ITS UTILITY AS A SIMULTANEOUS IN VITRO PROBE FOR CYP2B6 AND CYP3A4
ABSTRACT:
Endosulfan-a was metabolized to a single metabolite, endosulfan sulfate, in pooled human liver microsomes (Km = 9.8 jiM, Vmax = 178.5 pmol/mg/min). With the use of recombinant cytochrome P450 (rCYP) isoforms, we identified CYP2B6 (Km = 16.2 1 iM, Vmax = 11.4 nmol/nmol CYP/min) and CYP3A4 (Kmn = 14.4 jiM, Vm.zx = 1.3 nmol/nmol CYP/min) as the primary enzymes catalyzing the metabolism of endosulfan-a, albeit CYP2B6 had an 8-fold higher intrinsic clearance rate (CLin, = 0.70 pL/min/pmol CYP) than CYP3A4 (CLit = 0.09 jiL/min/pmol CYP). Using 16 individual human liver microsomes (HLM), a strong correlation was observed with endosulfan sulfate formation and S-mephenytoin N-demethylase activity of CYP2B6 (r 2 = 0.79) while a moderate correlation with testosterone 6-13-hyroxylase activity of CYP3A4 (r 2 = 0.54) was observed. Ticlopidine (5 VM), a potent CYP2B6 inhibitor, and ketoconazole (10 jiM), a selective CYP3A4 inhibitor, together inhibited approximately 90% of endosulfan-a metabolism in HLMs. Using six HLM samples, the percent total normalized rate (% TNR) was calculated to estimate the contribution of each CYP in the total metabolism of endosulfan-a. In five of the six HLMs used, the percent inhibition (% I) with ticlopidine and ketoconazole in the same incubation correlated with the combined % TNRs for CYP2B6 and CYP3A4. This study shows that endosulfan-a is metabolized by HLMs to a single metabolite, Sendosulfan sulfate, and that it has potential use, in combination with inhibitors, as an in vitro probe for CYP2B6 and 3A4 catalytic activities.
INTRODUCTION:
Endosulfan is an organochlorine pesticide and a contaminant at toxic superfund sites. It is currently applied as a broad spectrum insecticide to a variety of vegetables, fruits, cereal grains, and cotton (USEPA, 2002) . Endosulfan is sold under the tradename of Thiodan and as a mixture of two isomers, namely 70% a-and 30% P3-endosulfan (ATSDR, 2000) . Endosulfan exposure has been shown to increase rodent liver weights and elevate microsomal enzyme levels (Gupta and Gupta, 1977) . In mice, endosulfan exposure resulted in increased testosterone metabolism and clearance (Wilson and LeBlanc, 1998) . Studies involving children suggest that long term environmental exposure to endosulfan causes delayed male sexual maturation and reduced testosterone levels (Saiyed et al., 2003) . The mechanism by which endosulfan may exert these effects may involve its ability to activate the human pregnane X receptor (PXR) and induce the expression levels of cytochrome P450 (CYP or P450) enzymes, thereby increasing metabolic rates.
Prior to beginning an investigation of endosulfan's possible endocrine disrupting effects, we wished to examine its metabolic pathway in humans. To date, there are no published data on human metabolism of endosulfan nor on the possible contributions of CYP isoforms to its metabolism. Based on animal studies, a proposed metabolic pathway for endosulfan was published by the Agency for Toxic Substances and Disease Registry (ATSDR, 2000) and is shown in Fig.1 . A study using cats reported the immediate presence of endosulfan sulfate in the liver following intravenous administration of endosulfan (Khanna et al., 1979) . In rats administered with a single oral dose of 14C-endosulfan, the metabolites sulfate, lactone, ether, and diol were detected in their feces five days later (Dorough et al., 1978) . Analyses of human adipose tissue, placenta, umbilical cord serum, and milk samples demonstrated the presence of parent compound (a and P-endosulfan) and metabolites endosulfan sulfate, diol, lactone, and ether, albeit the sulfate was the predominant degradation product (Cerrillo et al., 2005) .
The present study determined that endosulfan-a is metabolized to a single metabolite, endosulfan sulfate, in human liver microsomes and its metabolism is primarily mediated by CYP2B6 (at high efficiency) and CYP3A4 (at low efficiency). CYP2B6 is recognized to be expressed at only 3 to 5 % of total P450s in human livers (Gervot et al., 1999; Lang et al., 2001) while CYP3A4 is known as the most abundant P450 isoform, expressed at 20-60% of total P450s in human liver (Guengerich, 1995) . The respective levels of CYP2B6 and CYP3A4 in human liver microsomes in combination with their strong affinity to endosulfan-a (Kn = 16.2 and 14.4 rM, respectively) and their corresponding clearance rates of endosulfan (CLit 0.70 and 0.09 piL/min/pmol CYP, respectively) presented a unique opportunity of investigating the potential of endosulfan-a to simultaneously probe for the in vitro catalytic activity of both CYP2B6 and 3A4.
MATERIALS and METHODS:
Chemicals. Endosulfan-a, the predominant isomer (70 %) in commercial endosulfan, was used in the study of endosulfan metabolism. Endosulfan-a, endosulfan sulfate, endosulfan diol, endosulfan ether, and endosulfan lactone reference materials were purchased from ChemService (West Chester, PA). Stock solutions of endosulfan-a and metabolites were prepared in acetonitrile (ACN) and stored at -20 'C. NADP+, glucose-6-phosphate, and glucose-6-phosphate dehydrogenase were purchased from Sigma-Aldrich (St. Louis, MO). HPLC grade water, ACN, EDTA, magnesium chloride, Tris, and all other chemicals not specified were purchased from Fisher Scientific (Pittsburgh, PA).
Ticlopidine, a potent mechanism-based chemical inhibitor to CYP2B6 (Richter et al., 2004) , and ketoconazole, a selective chemical inhibitor to CYP3A4 (Baldwin et al., 1995) were purchased from Sigma-Aldrich (St. Louis, MO). Stock solutions of ticlopidine were prepared in distilled water and stored at room temperature. Ketoconazole was dissolved in methanol and stock solutions were stored at 4°C. Metabolism assays. Preliminary studies were performed to determine the times and HLM protein concentrations which produced a linear metabolic rate for 50 ýLM of endosulfan-a.
Endosulfan sulfate formation was linear from 0.05 to 0.25 mg/mL protein and from 5 to 60 min of incubation. The solvent effects of dimethyl sulfoxide (DMSO), acetone, acetonitrile (ACN), methanol, ethanol, and isopropanol at 1% solvent concentration were also tested on endosulfan-a metabolism. There were no differences in the rates of endosulfan sulfate formation among the different solvents, with the exception of isopropanol which slightly inhibited formation of endosulfan sulfate (data not shown).
Based on the results of initial studies, 20 pM endosulfan-ci substrate concentration dissolved in ACN, 0.25 mg/mL protein concentration, and 30 min incubation time were used for subsequent metabolism assays, unless otherwise stated. Metabolism assays with HLMs utilized 100 mM potassium phosphate buffer (pH 7.4). Metabolism with rCYPs and rFMOs utilized the following buffers as recommended by BD Biosciences: 100 mM potassium phosphate (pH 7.4) for 1A1, 1A2, 3A4, 3A7, 2D6* 1, 3A5, and SF9 insect control; 50 mM potassium phosphate (pH 7.4) for 2B6, 2C8, 2C19, and 2El; 100 mM tris (pH 7.4) for 2C9*1, 2C18, and 4A1 1; 50 mM tris (pH 7.4) for 2A6; and 50 mM glycine (pH 9.5) for FMOs 1, 3, and 5. All buffers contained 3.3 mM MgC9 2 and 1mM EDTA.
A pre-incubation mixture of endosulfan-a (20 ýtM), HLMs (0.25 mg/mL) or rCYP isoforms (12.5 pmol), and buffer was prepared in 1.5 mL microcentrifuge tubes. This mixture was preincubated for 3 min at 37°C waterbath with minimal agitation. NADPH-regenerating system (final concentration of 0.25 mM NADP+, 2.5 mM glucose-6-phosphate, and 2 U/mL glucose-6-phosphate-dehydrogenase) was added to initiate reaction. The final assay volume was 250 ýIL.
Reactions were carried out for 30 min and terminated with 250 pL cold ACN, followed by pulse-wortexing. Samples were centrifuged at 16,000 rpm for 5 minutes and supernatants were analyzed in HPLC, as described in the HPLC analysis section below.
Inhibition studies. Protocols for CYP2136 and CYP3A4 inhibition by ticlopidine and ketoconazole utilized methods previously established by Richter et al (2004) and Nomeir et al. (2001) , respectively. In the case of ticlopidine, a mechanism-based inhibitor of CYP2B6, a 3 min pre-incubation at 37VC of ticlopidine (5 jiM) with HLMs (100 jig) or rCYPs (5 pmol) in 50 mM potassium phosphate buffer (with 3.3 mM MgC1 2 and lmM EDTA) in combination with an NADPH regenerating system (final concentration of 0.5 mM NADP+, 5 mM glucose-6-phosphate, and 4 U/mL glucose-6-phosphate dehydrogenase), occurred prior to the addition of endosulfan-a (20 jiM). In the case of ketoconazole, endosulfan-a (20 jiM) and ketoconazole (10 [tM) were pre-incubated along with 100 jig HLMs or 5 pmol rCYP in 50 mM potassium phosphate buffer for 3 min at 37°C prior to the addition of the NADPH regenerating system (final concentration of 0.25 mM NADP+, 2.5 mM glucose-6-phosphate, and 2 U/mL glucose-6-phosphate-dehydrogenase). In both cases, final reaction volumes were 250 jiL and reactions were terminated by the addition of 250 [tL cold ACN and processed as previously described.
High-performance liquid chromatography (HPLC) analysis. Metabolite formation was analyzed with a Shimadzu HPLC system consisting of an auto-injector (SIL-10AD VP), two pumps (LC-1 OAT), and a UV detector (SPD-1OA VP). Endosulfan-a and metabolites were separated by a Gemini C 18 column, 5 jm, 100 x 4.6 mm (Phenomenex) and identified with direct injection of reference compounds. The mobile phase for pump A consisted of 99% water and 1% phosphoric acid (pH 2.0) and for pump B, 100% ACN. The flow rate was 1 mL/min. A gradient methodology was used as follows: 0 to 3 minutes (60% ACN), 3 to 16 minutes (60-90% ACN), 16 to 19 minutes (90-60% ACN), and 19 to 20 minutes (60% ACN). The injection volume was 50 jiL and solutes were detected at 213 nm. Under these conditions, the retention times for endosulfan-a and endosulfan sulfate were 12.4 and 8.9 minutes, respectively.
Endosulfan-u and endosulfan sulfate peaks were quantified with calibration curves constructed from known concentrations of reference materials. The detection limit for endosulfan sulfate following the US Environmental Protection Agency's method detection limit procedure was 0.04 uM (CFR, 2006) . Data Analyses. Michaelis-Menten and Eadie-Hofstee plots were generated using Sigma Plot Enzyme Kinetics Module (Chicago, IL). Enzyme kinetic parameters Km and Vmax were determined using non-linear regression analysis with the Sigma Plot software.
Correlations of endosulfan sulfate formation with each CYP-specific catalytic activity or CYP contents were calculated with simple linear regression using the web-based Statcrunch program (www.statcrunch.com). p<0.05 was considered statistically significant.
To estimate the contributions of different CYP isoforms to metabolism of endosulfan-a, percent total normalized rates (% TNR) were calculated using the method described by (Rodrigues, 1999) . Briefly, metabolite formation rate (pmol/min/pmol rCYP) obtained from rCYP metabolism of the compound of interest is multiplied by the immunoquantified CYP content (pmol nCYP/mg) in native human liver microsomes, yielding the "normalized rate" (NR) expressed in pmol/min/mg microsomes. The NRs for each CYP involved in the metabolism of the compound of interest is summed up as the "total normalized rate" (TNR) (Rodrigues, 1999 
RESULTS:
Metabolism of endosulfan-a. Endosulfan-a at 50 jiM concentration was metabolized by pooled human liver microsomes (pHLM) to a single metabolite, endosulfan sulfate. Fig. 2 shows a representative HPLC chromatogram of this metabolism assay. The retention times for endosulfan-a and endosulfan sulfate were 12.23 and 8.73 min, respectively, in a 20 min HPLC run.
Cytochrome P450 screening. Cytochrome P450 (CYP) and flavin-containing monooxygenase (FMO) contributions to metabolism of endosulfan-c (20 uM) were investigated using 14 rCYPs and 3 rFMO commercially available human isoforms. Recombinant CYP2B6 predominantly mediated the formation of endosulfan sulfate by 8-fold (at 6.9 nmol/min/nmol CYP) over the next isoform (CYP3A4) with the next highest metabolite formation rate (at 0.8 nmol/min/nmol CYP). CYPs 2C 18, 2C 19, 2C9* 1, and 3A7 also showed metabolic activity, but at negligible levels ( Fig. 3) .
Kinetics of endosulfan-a metabolism. The kinetic parameters Km and Vmax were determined by incubating endosulfan-u (0.78-100 jiM) with pHLM (0.25 mg/mL), r-CYP2B6 or r-CYP3A4 (12.5 pmol). Calculated apparent K,n, V,,,, and CLit are shown in Table 1 Table 2 . Strong correlations were evident between endosulfan sulfate formation and CYP2B6 and 3A4 contents as determined by immunoquantitation (r 2 = 0.86 and 0.81, respectively). Likewise, there was a strong correlation between endosulfan sulfate formation and S-mephenytoin N-demethylase activity of CYP2B6 (r2 = 0.79). A less significant correlation was found with testosterone 6-03-hyroxylase activity of CYP3A4 (r 2 = 0.54). No significant correlations were found for the other selective CYP activities and respective contents.
Inhibition of endosulfan-a metabolism by ticlopidine and ketoconazole, selective chemical inhibitors for CYP2B6 and 3A4, respectively. Initially, the optimal concentrations of ticlopidine and ketoconazole needed to obtain maximal inhibition of endosulfan sulfate formation were tested in rCYP2B6 and rCYP3A4. Results of these experiments are shown in Fig. 5A-B . It was determined that 5 uM ticlopidine and 10 uM ketoconazole were optimal for subsequent inhibition studies.
Results of inhibition of endosulfan sulfate formation with ticlopidine (5 [M) or/and
ketoconazole (10 jM) are shown in Table 3 . Six individual HLMs were chosen for these studies, based on available immunoquantified CYP contents data supplied by manufacturer. These individual HLMs also represented various ranges of CYP contents (see Table 4 ). Inhibition of endosulfan sulfate formation by ketoconazole among the six individuals varied from 9 to 38%, implicating varying levels of CYP3A4 among these individuals. Similarly, the range of CYP2B6 involvement varied from 33 to 80%. The results show that inhibition of endosulfan metabolism with ketoconazole and ticlopidine were generally additive in all six HLMs.
Percent Total Normalized Rate (% TNR). % TNR was calculated to verify the percent inhibition (% I) results from this study (Table 4) . % TNR obtained from rCYPs can be directly related to % I obtained with native HLMs (Rodrigues, 1999) .
The % I from the combined incubation with ketoconazole and ticlopidine matched the sum of % TNRs of CYP2B6 and 3A4 in the metabolism of endosulfan-a in five of the six HLMs in this study (see Table 5 ).
DISCUSSION:
* In the present study, we found endosulfate sulfate as the only metabolite of endosulfan from incubations with HLMs. In mice exposed to a single dose of 14C-endosulfan, endosulfan sulfate concentrations were elevated in the liver, intestine, and visceral fat after 24 hours (Deema et al., 1966) . A study in rats administered a single oral dose of 1 4 C-endosulfan showed that the endosulfan metabolites diol, sulfate, lactone, and ether were found in the feces five days later (Dorough et al., 1978) . A recent study conducted in Spain where endosulfan is commonly used identified parent endosulfan and metabolites diol, sulfate, lactone and ether in adipose tissues, placenta, cord blood and human milk (Cerrillo et al., 2005) . These findings coupled with results of our study suggest that the diol, ether, and lactone metabolites may be the result of metabolic processes beyond those occurring in human liver microsomes.
Our kinetic studies with human liver microsomes as well as with CYP isoforms 2B6 and 3A4
produced monophasic Eadie-Hofstee plots, suggesting that endosulfan-a is metabolized either by one enzyme or by more than one enzyme with similar Km. A survey of 14 CYP isoforms demonstrated significant metabolism by CYP2B6, followed by 3A4, members of the 2C family and 3A7. Of these isoforms, CYP2B6 and 3A4 are likely to have the greatest impact based upon activity levels and relative abundance. Although CYP2C18 may be similar to CYP3A4 in capacity to metabolize endosulfan, it is poorly expressed in human livers (Goldstein, 2001) . Our kinetic studies demonstrated that CYP2B6 and CYP3A4 share similar binding affinities (Km of 16.2 and 14.4 riM, respectively) but vary significantly in maximum velocity. The resulting difference in clearance of endosulfan sulfate demonstrates that CYP2B6 is 8-fold more efficient than CYP3A4 in catalyzing the metabolism of endosulfan-a (see Table 1 ).
Initial inhibition studies utilizing monoclonal antibodies to CYP2B6 and 3A4 were abandoned due to their poor ability to inhibit endosulfan sulfate formation in the recombinant CYP isoforms (less than 30%; data not shown). This suggests that these monoclonal antibodies, although specific in inhibiting the metabolism of some substrates, may not be optimal inhibitors for endosulfan or other substrates. Hence, we used ticlopidine and ketoconazole, selective chemical inhibitors for CYP2B6 and 3A4 respectively, to characterize the contributions of these isoforms to endosulfan-a metabolism. At the concentrations used, these inhibitors did not significantly inhibit the activity of the other isoform examined (Fig 5) . It is of interest that in the six HLMs examined, the combined use of ketoconazole and ticlopidine resulted in inhibition of endosulfan sulfate formation which was generally similar to the results obtained with each inhibitor alone. For four individuals, the combined inhibition of CYP2B6 and 3A4 yielded values from 85 to 92%, yet two individuals retained significant ability to metabolize endosulfan following inhibition (HK23 and HG93 with 57 and 76% inhibition, respectively). To further explore the possibility that other CYPs were involved in metabolism for these individuals, the total normalized rates of metabolism for the CYP isoforms identified by screening efforts were investigated.
The % I from the combined incubation with ketoconazole and ticlopidine corresponded well with the combined % TNRs of CYP2B6 and 3A4 (Table 5) This is supported by a study in which a 26 % decrease was seen in N, N', N"-triethylene-.thiophosphoramide (tTEPA) inactivation of O-deethylation of 7-ethoxy-4-(trifluoromethyl)coumarin (7-EFC) in mutant CYP2B6 compared to wildtype 2B6 (Bumpus et al., 2005) . It is now known that CYP2B6 polymorphisms are common in Caucasians and that CYP2B6 is one of the most polymorphic human P450s (Lang et al., 2001) .
A number of substrate probes for CYP2B6 have been reported in the literature, including 7-ethoxy-4-trifluoromethylcoumarin (Code et al., 1997) , cyclophosphamide and ifosfamide (Huang et al., 2000) , S-mephenytoin (Heyn et al., 1996; Ko et al., 1998 ), bupropion (Faucette et al., 2000 Hesse et al., 2000) , and efavirenz (Ward et al., 2003) . The known substrate probes for CYP3A4 include testosterone, midazolam, nifedipine, and erythromycin (Yuan et al., 2002) .
The use of one substrate to simultaneously probe for the in vitro catalytic activity of CYP2B6
and CYP3A4 would be very advantageous. Based on the results of our inhibition studies,
endosulfan-a appears to be a strong candidate for this role.
In conclusion, endosulfan-a is metabolized to a single metabolite, endosulfan sulfate, by
HLMs. This metabolism is primarily mediated by CYP2B6 and CYP3A4. The strategies employed to demonstrate this were: 1) endosulfan-a metabolism by rCYPs, 2) correlation studies of endosulfan sulfate formation and CYP-selective activities or CYP immunoquantified contents in individual HLMs, and 3) inhibition studies using CYP2B6 and CYP3A4 selective chemical inhibitors. In addition, endosulfan-a may be utilized to simultaneously probe for the in-vitro 
